Translating neoadjuvant therapy into survival benefits: one size does not fit all
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Translating neoadjuvant therapy into survival benefits: one size does not fit all
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 13, Issue 9, Pages 566-579
Publisher
Springer Nature
Online
2016-03-22
DOI
10.1038/nrclinonc.2016.35
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Outcomes in patients (pts) with colorectal cancer (CRC) treated with oxaliplatin-based chemotherapy (OC) following prior oxaliplatin exposure.
- (2017) Nishin Anil Bhadkamkar et al. JOURNAL OF CLINICAL ONCOLOGY
- ER, PgR, Ki67, p27Kip1, and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab
- (2015) Sasagu Kurozumi et al. BMC CANCER
- Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015
- (2015) Dimitrios Zardavas et al. BREAST
- Long-Term Follow-Up After Preoperative Trastuzumab and Chemotherapy for HER2-Overexpressing Breast Cancer
- (2015) Erica L. Mayer et al. Clinical Breast Cancer
- Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease
- (2015) Eleonor Olsson et al. EMBO Molecular Medicine
- PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2–Targeted Therapies in Breast Cancer
- (2015) Ian J. Majewski et al. JOURNAL OF CLINICAL ONCOLOGY
- Toward understanding and exploiting tumor heterogeneity
- (2015) Ash A Alizadeh et al. NATURE MEDICINE
- Subclonal diversification of primary breast cancer revealed by multiregion sequencing
- (2015) Lucy R Yates et al. NATURE MEDICINE
- Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy
- (2015) Tari A. King et al. Nature Reviews Clinical Oncology
- Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
- (2015) Isaac Garcia-Murillas et al. Science Translational Medicine
- Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma
- (2015) Leticia De Mattos-Arruda et al. Nature Communications
- Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification
- (2015) Charlotte KY Ng et al. GENOME BIOLOGY
- Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab
- (2015) Roberto Salgado et al. JAMA Oncology
- Neoadjuvant Therapy in Breast Cancer as a Basis for Drug Approval
- (2015) Donald A. Berry et al. JAMA Oncology
- Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study
- (2014) H. Bonnefoi et al. ANNALS OF ONCOLOGY
- Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle
- (2014) L. De Mattos-Arruda et al. ANNALS OF ONCOLOGY
- Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)†
- (2014) G. von Minckwitz et al. ANNALS OF ONCOLOGY
- Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients
- (2014) H. R. Ali et al. ANNALS OF ONCOLOGY
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- (2014) R. Salgado et al. ANNALS OF ONCOLOGY
- Current and future role of neoadjuvant therapy for breast cancer
- (2014) Michael Untch et al. BREAST
- Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors
- (2014) Ozgur Sahin et al. CELL RESEARCH
- Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer
- (2014) J. A. Beaver et al. CLINICAL CANCER RESEARCH
- Phase I Dose-Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer
- (2014) A. Jo Chien et al. JOURNAL OF CLINICAL ONCOLOGY
- Pathologic Complete Response As a Potential Surrogate for the Clinical Outcome in Patients With Breast Cancer After Neoadjuvant Therapy: A Meta-Regression of 29 Randomized Prospective Studies
- (2014) Alfredo Berruti et al. JOURNAL OF CLINICAL ONCOLOGY
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- (2014) Patricia Cortazar et al. LANCET
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
- (2014) Evandro de Azambuja et al. LANCET ONCOLOGY
- Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
- (2014) Luca Gianni et al. LANCET ONCOLOGY
- Tumour heterogeneity and the evolution of polyclonal drug resistance
- (2014) Rebecca A. Burrell et al. Molecular Oncology
- Inference of Tumor Evolution during Chemotherapy by Computational Modeling and In Situ Analysis of Genetic and Phenotypic Cellular Diversity
- (2014) Vanessa Almendro et al. Cell Reports
- Use of Pertuzumab for the Treatment of HER2-Positive Metastatic Breast Cancer
- (2013) Leticia De Mattos-Arruda et al. ADVANCES IN THERAPY
- Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
- (2013) A. Schneeweiss et al. ANNALS OF ONCOLOGY
- Cancer heterogeneity: implications for targeted therapeutics
- (2013) R Fisher et al. BRITISH JOURNAL OF CANCER
- Challenges of Guarantee-Time Bias
- (2013) Anita Giobbie-Hurder et al. JOURNAL OF CLINICAL ONCOLOGY
- Response-Guided Neoadjuvant Chemotherapy for Breast Cancer
- (2013) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial
- (2013) Aron Goldhirsch et al. LANCET
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
- (2013) Sandra M Swain et al. LANCET ONCOLOGY
- Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
- (2013) David Cameron et al. LANCET ONCOLOGY
- Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial
- (2013) André Robidoux et al. LANCET ONCOLOGY
- Liquid biopsy: monitoring cancer-genetics in the blood
- (2013) Emily Crowley et al. Nature Reviews Clinical Oncology
- Circulating tumour cells and cell-free DNA as tools for managing breast cancer
- (2013) Leticia De Mattos-Arruda et al. Nature Reviews Clinical Oncology
- Pilot Studies for Personalized Cancer Medicine: Focusing on the Patient for Treatment Selection
- (2013) L. De Mattos-Arruda et al. ONCOLOGIST
- The Life History of 21 Breast Cancers
- (2012) Serena Nik-Zainal et al. CELL
- Defining the Benefits of Neoadjuvant Chemotherapy for Breast Cancer
- (2012) Anne F. Schott et al. JOURNAL OF CLINICAL ONCOLOGY
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
- (2012) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
- (2012) Valentina Guarneri et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of Pharmacokinetic Processes and Varied Dosing Schedules on the Dynamics of Acquired Resistance to Erlotinib in EGFR-Mutant Lung Cancer
- (2012) Jasmine Foo et al. Journal of Thoracic Oncology
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
- (2012) José Baselga et al. LANCET
- Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
- (2012) Michael Untch et al. LANCET ONCOLOGY
- Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
- (2012) Clara Montagut et al. NATURE MEDICINE
- Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
- (2012) Harry D. Bear et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
- (2012) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Advances in First-Line Treatment for Patients with HER-2+ Metastatic Breast Cancer
- (2012) L. De Mattos-Arruda et al. ONCOLOGIST
- Intratumor Heterogeneity: Seeing the Wood for the Trees
- (2012) T. A. Yap et al. Science Translational Medicine
- Pyoderma Gangrenosum Heralding Acute Leukemia for Months: Diagnostic Hint Written on the Skin
- (2011) Konstantin Schlick et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer
- (2011) A. M. Gonzalez-Angulo et al. MOLECULAR CANCER THERAPEUTICS
- Tumour evolution inferred by single-cell sequencing
- (2011) Nicholas Navin et al. NATURE
- Adjuvant Trastuzumab in HER2-Positive Breast Cancer
- (2011) Dennis Slamon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fitness Conferred by BCR-ABL Kinase Domain Mutations Determines the Risk of Pre-Existing Resistance in Chronic Myeloid Leukemia
- (2011) Kevin Leder et al. PLoS One
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
- (2010) Alexa B. Turke et al. CANCER CELL
- Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study
- (2010) Michael Untch et al. JOURNAL OF CLINICAL ONCOLOGY
- Genome remodelling in a basal-like breast cancer metastasis and xenograft
- (2010) Li Ding et al. NATURE
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Resiliency and Vulnerability in the HER2-HER3 Tumorigenic Driver
- (2010) D. N. Amin et al. Science Translational Medicine
- Predicting treatment effects using biomarker data in a meta-analysis of clinical trials
- (2010) Y. Li et al. STATISTICS IN MEDICINE
- Surgeon Recommendations and Receipt of Mastectomy for Treatment of Breast Cancer
- (2009) Monica Morrow JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Intensive Dose-Dense Compared With Conventionally Scheduled Preoperative Chemotherapy for High-Risk Primary Breast Cancer
- (2009) Michael Untch et al. JOURNAL OF CLINICAL ONCOLOGY
- Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
- (2009) Joel S. Parker et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognosis of Women With Metastatic Breast Cancer byHER2Status and Trastuzumab Treatment: An Institutional-Based Review
- (2009) Shaheenah Dawood et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas
- (2009) Felipe C Geyer et al. JOURNAL OF PATHOLOGY
- Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution
- (2009) Sohrab P. Shah et al. NATURE
- Analysis of Cancer Mutation Signatures in Blood by a Novel Ultra-Sensitive Assay: Monitoring of Therapy or Recurrence in Non-Metastatic Breast Cancer
- (2009) Zhenbin Chen et al. PLoS One
- Evolution of resistance and progression to disease during clonal expansion of cancer
- (2009) Richard Durrett et al. THEORETICAL POPULATION BIOLOGY
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
- (2008) Cornelia Liedtke et al. JOURNAL OF CLINICAL ONCOLOGY
- Detection of Mutations inEGFRin Circulating Lung-Cancer Cells
- (2008) Shyamala Maheswaran et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started